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Clinical implications of p53 tumor suppressor gene
mutation and protein expression in esophageal
adenocarcinomas: Results of a ten-year prospective study
Alan G. Casson, FRCSC,ab Susan C. Evans, BSc,b Amy Gillis, BSc,b Geoffrey A. Porter, MD,ac Paul Veugelers, PhD,c
S. Jane Darnton, PhD,b Duane L. Guernsey, PhD,b and Pierre Hainaut, PhDd
Objective: This study was undertaken to characterize the spectrum of p53 alterations
(mutations and protein expression) in surgically resected esophageal adenocarcino-
mas, and to correlate molecular alterations with clinicopathologic findings and
outcome.
Methods: Between 1991 and 2001, 91 consecutive patients with esophageal adeno-
carcinomas underwent subtotal esophagectomy. No patient received induction ther-
apy. Strict clinicopathologic criteria were used to define primary esophageal ade-
nocarcinomas. Genomic DNA was extracted from esophageal tumors, each matched
with histologically normal esophageal epithelium (internal control) from the resec-
tion margin. Polymerase chain reaction was used to amplify p53 exons 4 through 10.
Mutations were studied by single-strand conformation polymorphism analysis and
direct DNA sequencing. Immunohistochemical testing (monoclonal antibody DO7)
was used to evaluate p53 protein distribution.
Results: Five-year overall survival was 27.3%. No p53 alterations (mutations and/or
protein overexpression) were found in normal esophageal epithelium. A total of
57.1% (n  52) of tumors had p53 alterations (mutations and/or protein overex-
pression), which on univariate analysis were associated with poor tumor differen-
tiation (P  .001), advanced pTNM stage (P  .009), and number of involved
lymph nodes (0, 1-3, 3; P  .04). Patients with p53 alterations had significantly
reduced 5-year overall survival relative to patients with wild-type p53 (15% vs 46%;
P  .004). The p53 mutations were predominantly G:C to A:T transitions at CpG
dinucleotides (52.2%, 24/46)
Conclusions: We conclude that p53 alterations (mutations and/or protein overex-
pression) are a predictor of reduced postoperative survival after surgical resection of
esophageal adenocarcinomas and that p53 may be a clinically useful molecular
marker for stratifying patients in future clinical trials. Patterns of p53 mutations
suggest endogenous mutational mechanisms.
In North America and Europe there has been a marked change in theepidemiologic patterns of esophageal cancer during the past 3 decades.1,2Whereas the incidence of squamous cell carcinoma has remained steady,the incidence of adenocarcinomas of the esophagus and esophagogastricjunction has increased rapidly. The reasons for this change are largelyunknown and remain controversial. Epidemiologic studies3-6 have impli-
cated several lifestyle risk factors, including tobacco exposure, alcohol consump-
tion, diet, obesity, and gastroesophageal reflux for esophageal adenocarcinoma.
Recent molecular studies have also reported genetic alterations of various onco-
genes and tumor suppressor genes in esophageal tumors (for recent reviews see
references 7-10).
Tumor suppressor genes play important roles in the regulation of cell growth,
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differentiation, and DNA repair. The p53 tumor suppressor
gene appears to have a key role in human carcinogenesis,11
and p53 mutations are among the most frequent in human
cancers.12 With strict clinicopathologic criteria used to de-
fine adenocarcinomas of primary esophageal origin, we
reported p53 mutations in primary esophageal adenocarci-
nomas13 and associated premalignant Barrett epithelium in
1991.14 These original observations have now been con-
firmed by several investigators, documenting additional p53
mutations and changes in protein expression.15-20 However,
the clinical significance and potential applications of these
observations remain unclear.21-32
In February 1991, representing the first appointment of
the senior author (A. G. C.), a prospective study was initi-
ated to characterize the spectrum of p53 alterations in sur-
gically resected primary esophageal adenocarcinomas. Af-
ter a detailed molecular analysis of tumors banked during
the first 5 years, we reported significant associations be-
tween p53 alterations (mutations and/or protein overexpres-
sion) and tumor differentiation, lifestyle risk factors, and
survival.33 The objective of this report is to update the
results of the second 5-year interval (up to February 2001)
of this 10-year study, to document the spectrum of p53
mutations in primary esophageal adenocarcinomas, and to
further evaluate associations between p53 and clinicopath-
ologic findings and outcome.
Patients and Methods
Patients
This updated 10-year series comprised 91 sequentially accrued
patients (73 male and 18 female) treated by a single surgeon
(A.G.C.) between February 1991 and February 2001. All patients
had a histologic diagnosis of adenocarcinoma made from biopsy
samples obtained at esophagogastroscopy. Preoperative staging
consisted of computed tomography of the chest and upper abdo-
men. Endoscopic ultrasound and positron-emission tomography
were not available for staging. All patients were considered to have
locally resectable tumors, with no clinical evidence of distant
visceral metastases. No patient received induction chemotherapy
or radiotherapy. Subtotal esophagectomy was performed through a
right transthoracic (n  49) or transhiatal approach (n  42). A
potentially curative resection was performed, completely resecting
all macroscopic tumor, along with the thoracic and abdominal
esophagus and the lesser curvature of the stomach, to achieve a
minimum 5-cm distal resection margin.34 Regional lymph node
stations were resected extensively and mapped to document pat-
terns of metastasis.35 Reconstruction of the upper gastrointestinal
tract was achieved by transposing stomach through the posterior
mediastinum with cervical esophagogastrostomy (left side of
neck). Long-term postoperative follow-up comprised 3-monthly
office visits for the first 3 years, with visits every 6 months
thereafter. All reasonable attempts were made to confirm tumor
recurrence or metastasis cytologically or histologically with radio-
logically guided fine-needle aspiration or endoscopic biopsy tech-
niques.
Tumors
Immediately after esophageal resection, and in collaboration with
a consultant pathologist, resected esophageal tissues were exam-
ined, and representative sections of the primary tumor (comprising
80% malignant cells, with minimal necrosis) and histologically
normal esophageal epithelium adjacent to the proximal resection
margin were snap frozen in liquid nitrogen and stored in our
esophageal tumor bank at 80°C. Approval for banking of surgi-
cally resected esophageal tissues for molecular studies was ob-
tained from review boards for health science research at the
University of Western Ontario (London, Ontario, Canada) and
University of Toronto (Ontario, Canada) and from respective de-
partments of pathology. Tissues banked at Heartlands Hospital
(Birmingham, UK) were collected according to local protocols.
Since 1998 all tissues were banked at Dalhousie University in
accordance with the Canadian Tri-Council Policy “Statement on
Ethical Conduct for Research Involving Humans.”
All remaining esophageal tissues were processed according to
standard protocol by collaborating departments of pathology. Rep-
resentative sections were stained with hematoxylin and eosin and
examined by an independent consultant histopathologist. Serial
unstained, formalin-fixed, paraffin-embedded tissue sections were
used for subsequent immunohistochemical analyses. All tumors
were staged according to the International Union Against Cancer
(Union Internationale Contre Le Cancer; IUCC) classification on
the basis of pTNM subsets.36 Strict clinicopathologic criteria (Ta-
ble 1) were used to define primary esophageal adenocarcinomas
(Siewert type I),37 thereby excluding adenocarcinomas of the car-
dia (Siewert type II) or proximal (subcardia) gastric tumors (Siew-
ert type III). Proximal and distal resection margins were consid-
ered positive if tumor cells were present in any layer of the
esophageal or gastric wall. The radial (lateral) resection margin
was considered positive if tumor was present within 1 mm of the
inked surface.
Molecular and Immunohistochemical Analysis of the
p53 Gene
All molecular and immunohistochemical techniques were per-
formed at minimum in duplicate on coded samples by a laboratory
technician without knowledge of clinical correlative and outcome
data. Methodology has been described in detail previously else-
where.33 Briefly, genomic DNA was extracted from banked esoph-
ageal tissues (tumor and matched normal tissue as an internal
control), and p53 exons 4 through 10 were amplified by polymer-
ase chain reaction (PCR). Single-strand conformation polymor-
TABLE 1. Clinicopathologic criteria to define adenocarci-
nomas of primary esophageal origin
1. Barrett epithelium
2. 75% tumor mass involving the tubular esophagus
3. Direct invasion of periesophageal tissues
4. Minimal gastric involvement
5. Clinical symptoms of esophageal obstruction (eg, dysphagia)
Criteria may be evaluated radiologically, endoscopically, at surgery or
pathologically.13,33 For patients in whom Barrett epithelium (intestinal meta-
plasia defined histologically) cannot be demonstrated, criteria 2 through 5
must be established.
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phism (SSCP) analysis was used to screen for point mutations.
Direct DNA sequencing (forward and reverse) was used to confirm
the site and nature of each mutation. All samples were reamplified
from the original genomic DNA, followed by a second PCR and
SSCP with DNA sequencing.
A modified indirect immunoperoxidase technique was used to
study the distribution of p53 protein in formalin-fixed, paraffin-
embedded tissue sections. DO7, a murine monoclonal anti-p53
antibody (recognizing mutant and wild-type p53 protein) was used
at 1:50 dilution (Novocastra Laboratories Ltd, Newcastle upon
Tyne, UK). Controls were run in parallel with test sections and
included known positive and negative tissues (tissue controls),
matched histologically normal esophageal mucosa (internal con-
trol), and sections stained without the primary antibody (reagent
controls). Interpretation and scoring of tissue sections according to
intensity and proportion of positively staining cell nuclei have
previously been reported in detail.33 An individual was considered
to have altered p53 if a mutation was confirmed by sequencing or
by accumulation of p53 protein (immunopositivity) in tissue sec-
tions.
Data Collection and Statistical Analysis
Clinicopathologic data were prospectively collected and recorded
in a research database. Follow-up was complete for all patients
until February 2001. Differences in p53 alterations with respect to
gender, surgical approach, extent of resection, tumor differentia-
tion, pT stage, pN stage, UICC stage, and the number of resected
metastatic lymph nodes were tested with a 2 test, with the Fisher
exact test used if a cell contained fewer than 5 patients. The
prognostic importance of these variables, as well as those of p53
alterations, p53 mutations, and p53 protein expression, for overall
and disease-free survival after resection were compared with
Kaplan-Meier survival methods and tested with the log-rank test.
We applied multivariate Cox proportional hazards regression
methods to evaluate the independent importance of p53 for overall
and disease-free survival after resection. In this respect, we con-
sidered various combinations of variables that potentially con-
found the associations between p53 alterations and overall and
disease-free survival after resection. All analyses were performed
with SPSS for Windows 9.0 (SPSS Inc, Chicago, Ill).
Results
Mortality and Morbidity
Postoperative (30-day and in-hospital) mortality was 4.4%,
resulting from pulmonary embolus (n  2), aspiration (n 
1), and myocardial infarction (n  1). Postoperative course
was uncomplicated in 63.7% of patients (n  58/91), with
a median stay of 10 days (range 7-27 days). Overall, 33
patients (36.3%) had postoperative complications. Postop-
erative morbidity was associated with prolonged hospital-
ization that ranged from 9 to 63 days (median 20 days vs 10
days for uncomplicated course, P  .001).
Staging, Clinicopathologic Findings, and Outcome
Primary tumor histologic type was confirmed to be adeno-
carcinoma, and all tumors were considered to be of primary
esophageal origin after pathologic examination. Thirty-
three tumors were well differentiated (G1), 16 were mod-
erately differentiated (G2), and 42 were poorly differenti-
ated (G3). Tumors were staged as I (n  9), IIA (n  25),
IIB (n  7), III (n  39), and IV (n  11). The stage IV
classification was based on the presence of distant (nonre-
gional) lymph node metastases.35,36 A complete (R0) resec-
tion was confirmed histologically in 80.2% of patients (n 
73/91). Proximal esophageal and distal gastric resection
margins were histologically normal in all cases. Micro-
scopic residual tumor (R1) was documented in 14.3% of
patients (n  13/91) at the lateral tumor resection margin.
Macroscopic residual tumor (R2) was present in 5.5% of
patients (n  5/91), resulting from extracapsular nonre-
gional lymph node metastases. The number or regional
lymph nodes identified pathologically ranged from 2 to 26
(mean 10 nodes). Overall 5-year survival was 27.3%, with
a median survival of 19 months. Thirty-four patients are
currently alive with a median follow-up of 34 months.
Recurrent or metastatic disease was documented in 60.4%
of patients (n  55/91) and was predominantly systemic
(89.1%, n  49/55).
Alterations in p53
Overall, 57.1% of patients (n  52/91) in this updated
10-year series had p53 alterations (mutations and/or protein
overexpression). These data are summarized in Table 2.
Mutations alone were found in 50.5% of tumors (n 46/91)
throughout exons 4 through 10 of the p53 gene. Mutations
were missense (n  32) or truncating (n  14), the latter of
which comprised nonsense mutations (n  7), base inser-
tions (n  5), and base deletions (n  2). G:C to A:T single
base substitutions (n  28) were predominant, with 24 of
these changes at CpG dinucleotides. PCR-SSCP analysis of
matched normal DNA did not reveal any p53 mutations, and
DNA sequencing of tumors with negative results of PCR-
SSCP confirmed only the wild-type p53 sequence.
The p53 protein was demonstrated immunohistochemi-
cally in 36.2% of tumors (n  33/91). Cell nuclear immu-
noreactivity was heterogenous throughout tumor tissues,
and immunopositivity was scored on the basis of intensity
of cell nuclear staining and proportion of immunopositive
cells for each tissue section (Table 2), as described previ-
ously.33 No immunoreactivity was seen in matched histo-
logically normal esophageal mucosa or in any negative
control. No p53 mutations (all wild-type p53 confirmed by
sequencing) were found in 6 immunopositive tumors (Table
2).
Alterations in p53 and Clinicopathologic Observations
The associations between p53 alterations (mutations and/or
protein overexpression) and selected clinicopathologic vari-
ables are summarized in Table 3. The p53 alterations were
associated with higher stage tumors, lymph node metastasis,
and poor tumor differentiation.
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TABLE 2. The p53 alterations (mutations and protein accumulation) in primary esophageal adenocarcinomas
Stage* SSCP† Codon Base change Amino acid IHC‡
Exon 4 III  91§ G FS 
III  132 AAG-AGG Lys-Thr 
Exon 5 IIA  140 TGC-TAC Cys-Thr 
IV  154§ C FS 
III  158§ CGC-CAC Arg-His 
IIB  158§ CGC-CAC Arg-His 
IV  163§ TAC-TGC Tyr-Cys 
IV  174§ G FS 
IV  175 CGC-CAC Arg-His 
III  175§ CGC-CAC Arg-His 
IIA  175§ CGC-CAC Arg-His 
IIA  175§ CGC-CAC Arg-His 
IIA  175§ CGC-CAC Arg-His 
III  179§ CAT-TAT His-Tyr 
Exon 6 III  196§ CGA-TGA Arg-Stop 
IV  196§ CGA-TGA Arg-Stop 
III  213 CGA-TGA Arg-Stop 
Exon 7 III  234 TAC-TGC Tyr-Cys 
IIA  234§ TAC-AAC Tyr-Asn 
III  234§ TAC-TGC Tyr-Cys 
III  236 A FS 
I  236§ TA FS 
III  237 ATG-ATA Met-Ile 
IV  245 GGC-AGC Gly-Ser 
III  245 GGC-AGC Gly-Ser 
I  245§ GGC-AGC Gly-Ser 
III  246 ATG-ACG Met-Thr 
I  248 CGG-TGG Arg-Trp 
III  248§ CGG-TGG Arg-Trp 
III  249 AGG-AGT Arg-Ser 
III  250 CCC-CTC Pro-Leu 
Exon 8 III  271§ GAG-TAG Glu-Stop 
III  273 CGT-CAT Arg-His 
IIA  273 CGT-TGT Arg-Cys 
III  273§ CGT-CAT Arg-His 
IIA  273§ CGT-TGT Arg-Cys 
III  277 TGT-TTT Cys-Phe 
III  281 GAC-TAC Asp-Tyr 
I  282 CGG-TGG Arg-Tpr 
III  282§ CGG-TGG Arg-Trp 
IIA  306§ CGA-TGA Arg-Stop 
III  306§ CGA-TGA Arg-Stop 
Exon 9 IV  311§ AAC-CAC Asp-His 
III  316§ C FS 
Exon 10 IIA  334§ G FS 
IV  342§ CGA-TGA Arg-Stop 
Protein expression only III  
III  
III  
IIA  
III  
III  
IHC, Immunohistochemical analysis; Lys, lysine; Thr, threonine; Cys, cysteine; FS, frameshift; Arg, arginine; His, histidine; Tyr, tyrosine; Stop, stop codon;
Asn, asparagine; Met, methionine; Ile, isoleucine; Gly, glycine; Ser, serine; Trp, tryptophan; Pro, proline; Leu, leucine; Glu, glutamic acid; Phe, phenylalanine.
*UICC classification according to pTNM subsets.36
†Plus sign denotes an electrophoretic mobility shift indicative of a point mutation, confirmed by DNA sequencing to define the codon and base change;
minus sign denotes no electrophoretic mobility shift (sequence analysis confirmed wild-type p53).
‡Immunonegative sections are denoted by minus signs. A composite scoring system33 of intensity and proportion of immunopositive tumor cell nuclei was
used to determine p53 protein accumulation, denoted by plus signs.
§Previously reported mutations.33
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Alterations in p53 and Survival
Prognostic variables of overall and disease-free survival are
summarized in Table 4. The p53 alterations (mutations
and/or protein overexpression) were associated with re-
duced overall survival (odds ratio 2.26, 95% confidence
interval 1.27-4.00, P  .004; Figure 1). Similar observa-
tions were made for disease-free survival (odds ratio 2.78;
95% confidence interval 1.51-5.13, P  .001). The impor-
tance of p53 alterations (mutations and/or protein overex-
pression) was stronger for disease-free survival than for
overall survival. Of all prognostic variables evaluated by
multivariate analysis, only tumor stage was statistically
significantly associated with survival, with p53 alterations
having no statistically significant association when evaluat-
ing both overall and disease-free survival.
Discussion
To explore potential clinical applications for the p53 tumor
suppressor gene, this prospective study was initiated to
characterize the spectrum of p53 alterations (mutations and
protein expression) in a well-defined and well-staged series
of surgically resected esophageal adenocarcinomas. We
studied 91 tumors, documenting p53 alterations (mutations
and/or protein overexpression) in 52 (57.1%). In keeping
with results obtained from our earlier analysis of the initial
5 years of this 10-year study,33 we have confirmed statisti-
cally significant associations between p53 alterations and
advanced tumor stage, lymph node metastasis, poor tumor
differentiation, and reduced overall and disease-free sur-
vival.
In normal cells the p53 gene, localized to chromosome
17p13, is thought to act as a transcription factor with a wide
range of biologic functions, including regulation of cell-
cycle checkpoints, apoptosis, and maintenance of genomic
integrity.11 The gene encodes a 53-kd phosphoprotein that
does not accumulate to significant levels in normal cells
because of rapid turnover (half-life 2-15 minutes). In re-
sponse to various cellular signals, the p53 protein is stabi-
lized and becomes capable of transactivating several down-
stream target genes. These complex regulatory molecular
mechanisms are thought to prevent DNA replication after
genomic damage, either by arresting cells in G1 and allow-
ing more time for DNA repair or by inducing apoptosis (cell
death) of cells that contain damaged DNA.11,38-42
Point mutations of the p53 tumor suppressor gene are
among the most frequent molecular alterations in human
malignancies,7,12 suggesting that loss of p53 function is
critical to tumorigenesis. Missense mutations in conserved
regions of the DNA-binding domain of p53 (exons 5-8)
result in the loss of ability of p53 to bind DNA in a
sequence-specific manner, preventing the gene from trans-
activating its physiologic molecular targets.43 Alternative
molecular mechanisms of inactivation have also been de-
scribed, including accelerated protein degradation through
interaction with cellular (mdm2) or viral (HPV E6) oncop-
roteins and cytoplasmic retention and accumulation of wild-
type p53.44,45 However, it is not known with certainty which
of these p53 activities is the most critical for tumorigenesis,
and p53 activity may further be influenced by cell type and
epigenetic modifiers. Regardless of the molecular mecha-
nism, the resulting loss of p53 function is thought to en-
hance genomic instability in cancer cells, predisposing to-
ward accumulation of multiple molecular genetic
alterations.
In addition to providing further insight into fundamental
biologic mechanisms associated with tumor development,
there has been considerable interest in potential clinical
applications of p53 for early diagnosis, staging, prognosis,
as a predictor of cytotoxic drug sensitivity or resistance, and
as a molecular target for gene therapies.46,47 Such ap-
proaches that use p53 and other molecular biomarkers are
particularly important for esophageal cancer, because long-
term prognosis for this disease is poor.
TABLE 3. Proportion of p53 alterations for selected clini-
copathologic parameters
p53
Alterations
P valueNo. %
Gender .542
Male 42/73 58
Female 10/18 56
Surgical approach .262
Right thoracotomy 30/49 61
Transhiatal 22/42 52
Extent of resection .010
Complete (R0) 37/73 51
Incomplete (R1, R2) 15/18 83
Tumor differentiation (grade) .002
Well differentiated (G1) 11/33 33
Moderately differentiated (G2) 10/16 63
Poorly differentiated (G3) 31/42 74
T stage .079
pT1 4/9 44
pT2 7/19 37
pT3 35/56 63
pT4 6/7 86
N stage .014
pN0 15/36 42
pN1 37/55 67
UICC stage .009
I 4/9 44
IIA 9/25 36
IIB 2/7 29
III 28/39 72
IV 9/11 82
No. of metastatic nodes resected .044
0 15/36 42
1-3 17/27 63
3 20/28 71
Casson et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 5 1125
G
TS
TABLE 4. Univariate analysis of selected prognostic factors for survival after surgical resection of primary esophageal
adenocarcinomas
5-y survival
(%)
Odds
ratio
95% Confidence
interval P value
Overall survival
Gender .07
Male 22
Female 47 0.52 0.25-1.06
Surgical approach .61
Right thoracotomy 27
Transhiatal 29. 0.87 0.52-1.50
Extent of resection .0001
Complete (R0) 33
Incomplete (R1, R2) 0 6.03 3.02-12.06
Tumor differentiation (grade) .0001
Well differentiated (G1) 56
Moderately differentiated (G2) 18 2.70 1.12-6.49
Poorly differentiated (G3) 7 5.62 2.86-11.03
T stage .0006
pT1 100
pT2 43 4.7 0.60-38.90
pT3 17 9.8 1.35-71.90
pT4 0 32.6 3.90-281.80
N stage .0001
pN0 60
pN1 5 8.9 4.2-18.80
International Union Against Cancer stage .0001
I 100
IIA 55 2.7 0.34-21.70
IIB 14 17.0 1.91-151.31
III 6 22.4 2.86-175.89
IV 0 32.6 3.90-281.80
No. of metastatic lymph nodes resected .0001
0 60
1-3 7 6.4 2.87-14.29
3 4 18.9 8.03-44.2
p53 Alterations .004
Mutation or protein expression 15
Wild-type 46 2.26 1.27-4.00
p53 Mutations .080
Mutation present 17
Wild-type 40 1.59 0.93-2.72
p53 Protein expression .052
Immunopositive 20
Immunonegative 32 1.69 1.00-2.86
Disease-free survival
Gender .74
Male 24
Female 41 0.64 0.32-1.28
Surgical approach .20
Right thoracotomy 27
Transhiatal 30 0.71 0.41-1.21
Extent of resection .0001
Complete (R0) 35
Incomplete (R1, R2) 0 7.32 3.80-14.21
Tumor differentiation (grade) .0001
Well differentiated (G1) 70
Moderately differentiated (G2) 14 5.37 2.12-13.62
Poorly differentiated (G3) 0 9.96 4.49-22.09
T stage .002
pT1 50
pT2 36 5.15 0.66-39.88
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To date few studies have critically evaluated the prog-
nostic significance of p53 alterations in esophageal adeno-
carcinoma. In a combined series of adenocarcinomas (n 
24) and squamous cell carcinomas (n  63) of the esoph-
agus, p53 protein accumulation (shown immunohistochemi-
cally) was reported in 19 (79%) adenocarcinomas but was
not associated with outcome after surgical resection.24 One
further combined series of esophageal tumors (n  21
adenocarcinomas, n  46 squamous cell carcinomas) also
reported that p53 mutations (40.5%) and p53 protein accu-
mulation (59.5%) were not related to postoperative surviv-
al.48 By contrast, improved survival of patients with adeno-
carcinomas with p53 protein overexpression (50% of
tumors) was reported by Sauter and colleagues25 in a phase
II study of 24 patients treated with chemotherapy (5-flu-
orouracil and mitomycin C), radiotherapy (60 Gy), and
surgical resection. In addition to our initial report of 48
patients with esophageal adenocarcinomas who underwent
surgical resection alone,33 two studies have now demon-
strated poor prognosis for patients with esophageal adeno-
carcinomas found to have p53 mutations. Ribeiro and co-
workers29 evaluated 42 patients with esophageal
adenocarcinoma treated by chemotherapy (5-fluorouracil,
cisplatin, and -interferon), radiation therapy (45 Gy) and
surgery, correlating p53 mutations (40.5%) and p53 protein
expression (59.5%) with significantly reduced overall and
disease-free survival. Comparable results were also recently
reported by Schneider and colleagues,31 who found that p53
mutations (50.8%) were associated with significantly re-
duced survival in a series of 59 patients who underwent
potentially curative surgical resection of esophageal adeno-
carcinoma.
Several factors may account for the conflicting results
reported in the preceding studies, and the limitations of
evaluating molecular biomarkers in clinical correlative stud-
ies are well known.49-51 Such limitations include use of
variable treatment strategies (eg, use of induction chemo-
therapy or radiotherapy, different operative procedures),
relatively low patient numbers to achieve sufficient statis-
tical power, lack of a strict definition for primary esophageal
adenocarcinomas, incomplete pathologic staging, differing
techniques for evaluating p53 (mutation analysis vs immu-
nohistochemical analysis), and technical issues related to
tumor heterogeneity.
Although we have attempted to overcome such limita-
tions where possible, it is important to note that these data
reflect a selected series of patients referred for potentially
curative esophageal resection at tertiary university centers
and may therefore not necessarily be representative of
esophageal adenocarcinoma in the general population.
However, the surgical results, prognostic factors (eg, stage),
and survival rates in this study are comparable with those in
other recent series reporting surgical outcomes with esoph-
ageal cancer.52-56 In contrast to previously reported studies
TABLE 4. Continued
5-y survival
(%)
Odds
ratio
95% Confidence
interval P value
pT3 24 9.51 1.30-69.46
pT4 0 42.30 4.92-363.44
N stage .0001
pN0 59
pN1 6 8.33 4.02-17.26
UICC stage .0001
I 50
IIA 64 2.27 0.28-18.14
IIB 0 19.12 2.27-161.19
III 9 19.79 2.62-147.37
IV 0 101.48 4.92-363.44
No. of metastatic lymph nodes resected .0001
0 59
1-3 13 5.38 2.41-12.02
3 0 22.84 9.81-53.15
p53 Alterations .001
Mutation and/or protein overexpression 9
Wild-type 54 2.78 1.51-5.13
p53 Mutations .010
Mutation present 9
Wild-type 48 2.07 1.18-3.62
p53 Protein expression .020
Immunopositive 0
Immunonegative 36 1.90 1.11-3.23
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evaluating the prognostic significance of p53 in esophageal
adenocarcinoma,25,29 no patient received induction therapy
(as is current clinical practice in our center), and all patients
were treated by a single surgeon with consistent operative
technique. Of particular importance was our use of strict
clinicopathologic criteria13,33 to define adenocarcinomas of
primary esophageal origin (Siewert type I).37 The recent
demonstration of molecular differences between adenocar-
cinomas of the esophagus (Siewert type I) and cardia (Siew-
ert type II), suggesting that these represent different patho-
logic entities, may therefore influence future treatment
strategies.57 During the past decade, we have used a differ-
ent operative approach to resect cardia adenocarcinomas
(Siewert type II): a left thoracoabdominal extended gastrec-
tomy, incorporating the distal thoracic esophagus to the
level of the inferior pulmonary vein, with esophagojejunal
Roux-en-Y reconstruction.
Techniques to evaluate p53 may further account for
discordant results between previously reported prognostic
studies. The advantages and limitations of immunohisto-
chemical analysis of p53 protein versus molecular analysis
of p53 mutations have previously been addressed in de-
tail.58,59 In this study, either approach was found to have a
statistical association with survival, but the combination of
p53 alterations (mutations and/or protein overexpression)
was most significant.
Molecular analysis of the p53 gene has provided valu-
able fundamental information regarding the biology of
esophageal adenocarcinoma.60 A high proportion of p52
mutations (30.4%) found in this study were truncating mu-
tations that resulted in a null-protein phenotype and are
therefore undetectable by immunohistochemical means. In
contrast, some tumors were immunopositive, with no mu-
tations in p53. Rare instances of mutations outside p53
exons 4 through 10 have been described,61 but there is also
evidence that mechanisms other than point mutation may
result in p53 protein accumulation and inactivation (eg,
cytoplasmic p53 protein accumulation in a subset of breast
cancer62 and in neuroblastoma45).
In agreement with these considerations, our results indi-
cate that the combination of mutation analysis and immu-
nohistochemical analysis discriminates a group of tumors
with more aggressive clinical and biologic properties. This
biologic effect is reflected to some extent by an increasing
statistically significant relationship between p53 status (mu-
tations, protein overexpression, or both) and reduced dis-
ease-free survival relative to overall survival. Furthermore,
esophageal adenocarcinomas with p53 alterations tend to be
more poorly differentiated than tumors with wild-type p53,
suggesting that the p53 tumor suppressor gene contributes
to maintain cancer cells in a low-differentiation, high-pro-
liferation state. Similar associations between p53 and poor
tumor differentiation have previously been reported for
other upper aerodigestive tract tumors, including non–small
cell lung cancer,63 and for head and neck cancers.64
Biologically, one of the most interesting lessons derived
from analysis of p53 mutations in esophageal cancer relates
to patterns of mutations.60,61 Patterns of p53 mutations in
squamous cell carcinoma of the esophagus are predomi-
nantly transitions or transversions occurring at A:T base
pairs (suggesting a relationship to metabolites of ethanol, a
well-defined risk factor for squamous cell carcinomas), or G
to T transversions (a characteristic mutation attributed to
benzo[a]pyrine, suggesting an association with tobacco).61
For esophageal adenocarcinomas, however, predominant
mutations are G:C to A:T transitions at CpG dinucleotides
(52.2% in this study). A review of all published human p53
mutations (see IARC p53 mutation database at http://
www.iarc.fr/p53/index.html) indicates that esophageal ade-
nocarcinomas are the cancer type with the highest propor-
tion of such mutations. There is now solid molecular
evidence that these mutations primarily arise through en-
dogenous mechanisms, involving the spontaneous deamina-
tion into thymine of the 5 methylated cytosine that fre-
quently occurs at CpG dinucleotides.61 This mechanism is
enhanced by exposure to oxyradicals and nitroradicals. In
colon cancer, Ambs and associates65 demonstrated a direct
correlation between the levels of expression of nitric oxide
synthase 2 and the rate of formation of G:C to A:T transition
at CpG dinucleotides, incriminating overproduction of nitric
oxide as a major causative factor. Our data support the
hypothesis that chronic stress, in particular that related to
Figure 1. Kaplan-Meier survival curves for patients after surgical
resection of primary esophageal adenocarcinoma categorized by
p53 status. Statistically significantly improved overall survival
was seen for patients (n  39) with tumors found to have wild-
type p53 relative to patients (n  52) with tumors showing p53
alterations (mutations and/or protein overexpression).
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gastroesophageal reflux, may result in local overproduction
of nitric oxide in normal and metaplastic esophageal mu-
cosa, thus enhancing the rate of formation of spontaneous
p53 mutations. This observation may provide a basis for
chemopreventive approaches aimed at reducing the levels of
nitric oxide production in the lower esophagus of individ-
uals at increased risk for esophageal adenocarcinoma.
It seems likely that further progress with esophageal
adenocarcinoma will only be made with a clearer under-
standing of its tumor biology. Recent advances in molecular
technology will also permit the identification of multiple
biomarkers and global gene expression profiles to be studied
in esophageal tissues.66 Barrett esophagus is an excellent
model to study early molecular alterations associated with
tumorigenesis. Several early molecular alterations in Barrett
epithelium have now been described8,67 and will probably
form the basis of further strategies for early detection,
prevention and therapy.68
For expert technical advice and assistance regarding molecular
analysis of the p53 gene, we thank Giselle Martel-Planche (IARC,
Lyon, France). We thank Sasha Eskandarian (Lunenfeld Research
Institute, Toronto, Ontario, Canada) for performing the initial
molecular and immunohistochemical studies. For follow-up, we
thank the following clinical trials nurses and administrative assis-
tants: Bev Neskas, Sue Troyan, RN, and Natalie Zankowicz, RN
(London, Ontario, Canada); Susan Rosgen, RN, and Frances Hui
(Toronto, Ontario, Canada); and Dianne Russell (Halifax, Nova
Scotia, Canada). We also thank participating patients, their fami-
lies and personal physicians, and the Cancer Intelligence Unit
(West Midlands, Birmingham, UK). The following consultant
pathologists were invaluable for expert clinical histopathologic
review at each respective center: Dr M. Troster (London, Ontario,
Canada); Dr M. Redston (Toronto, Ontario, Canada); Dr J. New-
man and Professor J. Crocker (Birmingham, UK); and Dr D.
Malatjalian (Halifax NS). We thank John Fris for data manage-
ment.
References
1. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence
of esophageal and gastric carcinoma in the United States. Cancer.
1998;83:2049-53.
2. Powell J, McConkey CC. The rising trend in oesophageal adenocar-
cinoma and gastric cardia. Eur J Cancer Prev. 1992;1:265-9.
3. Zhang ZF, Kurtz RC, Sun M, Karpeh M, Yu GP, Gargon N, et al.
Adenocarcinomas of the esophagus and gastric cardia: Medical con-
ditions, tobacco, alcohol, and socioeconomic factors. Cancer Epide-
miol Biomarkers Prev. 1996;5:761-8.
4. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL,
Chow WH, et al. Tobacco, alcohol, and socioeconomic status and
adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer
Inst. 1997;89:1277-84.
5. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gas-
troesophageal reflux as a risk factor for esophageal adenocarcinoma.
N Engl J Med. 1999;340:825-31.
6. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan
TL, et al. Nutrient intake and risk of subtypes of esophageal and
gastric cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1055-62.
7. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esopha-
geal cancer and their relevance to etiology and pathogenesis: a review.
Int J Cancer (Pred Oncol). 1996;69:225-35.
8. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K,
Casson AG, et al. Molecular evolution of the metaplasia-dysplasia-
adenocarcinoma sequence in the esophagus. Am J Pathol. 1999;154:
965-73.
9. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of
Barrett’s adenocarcinoma. Ann Surg. 2001;233:322-37.
10. Chen X, Yang CS. Esophageal adenocarcinoma: a review and per-
spectives on the mechanism of carcinogenesis and chemoprevention.
Carcinogenesis. 2001;22:1119-29.
11. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112-26.
12. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T,
Hollstein M, et al. IARC database of p53 gene mutations in human
tumors and cell lines: updated compilation, revised formats and new
visualization tools. Nucleic Acids Res. 1998; 26:205-13.
13. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA.
Oncogene activation in esophageal cancer. J Thorac Cardiovasc Surg.
1991;102:707-10.
14. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA.
p53 gene mutations in Barrett’s epithelium and esophageal cancer.
Cancer Res. 1991;51:4495-9.
15. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu S, et
al p53 mutation and protein accumulation during multistage human
esophageal carcinogenesis. Cancer Res. 1992;52:6092-7.
16. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn
G, et al. p53 mutations in Barrett’s adenocarcinoma and high-grade
dysplasia. Gastroenterology. 1994;106:1589-95.
17. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F,
et al. TP53 gene mutations and p53 protein immunoreactivity in
malignant and premalignant Barrett’s esophagus. Gastroenterology.
1994;107:102-18.
18. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SE. Base
transitions at CpG dinucleotides in the p53 gene are common in
esophageal adenocarcinoma. Cancer Res. 1995;55:3406-11.
19. Moskaluk CA, Heitmiller R, Zahurak M, Schwab D, Sidransky D,
Hamilton SR. p53 and p21WAF1/CIP1/SDI1 gene products in Barrett
esophagus and adenocarcinoma of the esophagus and esophagogastric
junction. Hum Pathol. 1996;27:1211-20.
20. Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH,
Becker K, et al. Mutations of p53 in Barrett’s esophagus and Barrett’s
cancer: a prospective study of 98 cases. J Thorac Cardiovasc Surg.
1996;111:323-33.
21. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert
HE. p53 protein expression and prognosis in squamous cell carcinoma
of the esophagus. Cancer. 1994;74:2218-23.
22. Jones DR, Davidson AG, Summers CL, Murray GF, Quinlan DC.
Potential application of p53 as an intermediate biomarker in Barrett’s
esophagus. Ann Thorac Surg. 1994;57:598-603.
23. Rice TW, Goldblum JR, Falk GW, Tubbs RR, Kirby TJ, Casey G. p53
immunoreactivity in Barrett’s metaplasia, dysplasia, and carcinoma.
J Thorac Cardiovasc Surg. 1994;108:1132-7.
24. Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C,
Matthews HR. Expression of p53 protein in oesophageal carcinoma:
clinicopathological correlation and prognostic significance. Br J Surg.
1994;81:1623-6.
25. Sauter ER, Keller SM, Erner SM. p53 correlates with improved
survival in patients with esophageal adenocarcinoma. J Surg Oncol.
1995;58:269-73.
26. Casson AG, Kerkvliet N, O’Malley F. Prognostic value of p53 protein
in esophageal adenocarcinoma. J Surg Oncol. 1995;60:5-11.
27. Monges GM, Seitz JF, Giovannini MF, Gouvernet JM, Torrente MA,
Hassoun JA. Prognostic value of p53 protein expression in squamous
cell carcinoma of the esophagus. Cancer Detect Prev. 1996;20:63-7.
28. Uchino S, Saito T, Inomata M, Osawa N, Chikuba K, Etoh K, et al.
Prognostic significance of the p53 mutation in esophageal cancer. Jpn
J Clin Oncol. 1996;26:287-92.
29. Ribeiro U, Finkelstein SD, Safatle-Riberio AV, Landreneau RJ,
Clarke MR, Bakker A, et al. p53 sequence analysis predicts treatment
response and outcome of patients with esophageal carcinoma. Cancer.
1998;83:7-18.
30. Krasna MJ, Mao YS, Sonett JR, Tamura G, Jones R, Suntharalingam
M, et al. p53 gene protein overexpression predicts results of trimo-
Casson et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 5 1129
G
TS
dality therapy in esophageal cancer patients. Ann Thorac Surg. 1999;
68:2021-5.
31. Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S,
Mizumoto S, et al. p53 mutational status improves estimation of
prognosis in patients with curatively resected adenocarcinoma in Bar-
rett’s esophagus. Clin Cancer Res. 2000;6:3153-8.
32. Aloia TA, Harpole DH, Reed CE, Allegra C, Moore MB, Herndon JE,
et al. Tumor marker expression is predictive of survival in patients
with esophageal cancer. Ann Thorac Surg. 2001;72:859-66.
33. Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin
J, Ozcelik H. p53 alterations in oesophageal cancer: association with
clinicopathological features, risk factors, and survival. J Clin Pathol:
Mol Pathol 1998;51:71-9.
34. Casson AG, Darnton SJ, Subramanian S, Hiller L. What is the opti-
mum distal resection margin for esophageal carcinoma? Ann Thorac
Surg. 2000;69:205-9.
35. Casson AG, Rusch VW, Ginsberg RJ, Zankowicz N, Finley RJ.
Lymph node mapping of esophageal cancer. Ann Thorac Surg. 1994;
58:1569-70.
36. Sobin LH, Wittekind C, editors. TNM classification of malignant
tumours. 5th ed. New York: Wiley-Liss; 1997. p. 54-7.
37. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oe-
sophagastric junction. Br J Surg. 1998;85:1457-9.
38. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW.
Participation of p53 protein in the cellular response to DNA damage.
Cancer Res. 1991;51:6304-11.
39. Zahn Q, Carrier F, Fornace AJ. Induction of cellular p53 activity by
DNA-damaging agents and growth arrest. Mol Cell Biol. 1993;13:
4242-50.
40. Tishler RB, Calderwood SK, Coleman CN, Price BD. Increases in
sequence specific DNA binding by p53 following heat treatment with
chemotherapeutic and DNA damaging agents. Cancer Res. 1993;53:
2212-6.
41. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell.
1997;88:323-31.
42. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The
p53 network. J Biol Chem. 1998;273:1-4.
43. Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Oliver
M, Hainaut P, et al. Integrating mutation data and structural analysis
of the TP tumor-suppressor protein. Hum Mutat. 2002;19:149-64.
44. Riou G, Le MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of
p53 gene mutation and nuclear overexpression of p53 protein in
inflammatory breast carcinoma. J Natl Cancer Inst. 1993;85:1765-7.
45. Moll UM, La Quaglia M, Benard J, Riou G. Wild-type p53 protein
undergoes cytoplasmic sequestration in undifferentiated neuroblasto-
mas but not in differentiated tumors. Proc Natl Acad Sci U S A.
1995;92:4407-11.
46. Harris CC. Structure and function of the p53 tumor suppressor gene:
clues for rational cancer therapeutic strategies. J Natl Cancer Inst.
1996;88:1442-55.
47. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 muta-
tions. Cell Mol Life Sci. 1999;54:64-75.
48. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, et al.
p53 protein accumulation and p53 mutation in esophageal carcinoma:
a molecular and immunohistochemical study with clinicopathologic
correlation. Cancer. 1997;79:425-32.
49. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM,
et al. Tumor marker utility grading system: a framework to evaluate
clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456-66.
50. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are
we being misled? Ann Intern Med. 1996;125:605-13.
51. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M,
et al. Phases of biomarker development for early detection of cancer.
J Natl Cancer Inst. 2001;93:1054-61.
52. Steup WH, De Leyn P, Deneffe G, Van Raemdonck D, Coosemans W,
Lerut T. Tumors of the esophagogastric junction: long-term survival in
relation to the pattern of lymph node metastasis and a critical analysis
of the accuracy or inaccuracy of pTNM classification. J Thorac
Cardiovasc Surg. 1996;111:85-95.
53. Ellis FH, Heatley GJ, Krasna MJ, Williamson WA, Balogh K. Esopha-
gogastrectomy for carcinoma of the esophagus and cardia: a compar-
ison of findings and results after standard resection in three consecu-
tive eight-year intervals with improved staging criteria. J Thorac
Cardiovasc Surg. 1997;113:836-48.
54. Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Pairolero
PC. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann
Thorac Surg. 2001;71:1803-8.
55. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred
E, et al. Transthoracic esophagectomy with radical mediastinal and
abdominal lymph node dissection and cervical esophagogastrostomy
for esophageal carcinoma. Ann Thorac Surg. 2001;72:1918-25.
56. van Sandick JW, van Lanschot JB, ten Kate FJ, Tijssen JG, Obertop
H. Indicators of prognosis after transhiatal esophageal resection with-
out thoracotomy for cancer. J Am Coll Surg. 2002;194:28-36.
57. Taniere P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec
JY, Montesano R, et al. Molecular and clinical differences between
adenocarcinomas of the esophagus and of the gastric cardia. Am J
Pathol. 2001;158:33-40.
58. Wynford-Thomas D. p53 in tumor pathology: can we trust immuno-
cytochemistry? J Pathol. 1992;166:329-30.
59. Elledge RM. Assessing p53 status in breast cancer prognosis: where
should you put the thermometer if you think your p53 is sick? J Natl
Cancer Inst. 1996;88:141-3.
60. Hainaut P, Vahakangas K. p53 as a sensor of carcinogenic exposures:
mechanisms of p53 protein induction and lessons from p53 gene
mutations. Pathol Biol. 1997;45:833-44.
61. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand
mutations. Adv Cancer Res. 2000;77:81-137.
62. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in
breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U
S A. 1992;89:7262-6.
63. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, et al. p53
expression: predicting recurrence and second primary tumors in head
and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:519-
29.
64. Dalquen P, Sauter G, Torhorst J, Schultheiss E, Jordan P, Lehmann S,
et al. Nuclear p53 overexpression is an independent prognostic pa-
rameter in node-negative non–small cell lung carcinoma. J Pathol.
1996;178:53-8.
65. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM,
Harrington AM, et al. Relationship between p53 mutations and induc-
ible nitric oxide synthase expression in human colorectal cancer.
J Natl Cancer Inst. 1999;91:86-8.
66. Selaru FM, Zou T, Xu Y, Shustova V, Yin J, Mori Y, et al. Global
gene expression profiling in Barrett’s esophagus and esophageal can-
cer: a comparative analysis using cDNA microarrays. Oncogene.
2002;21:475-8.
67. Casson AG. Role of molecular biology in the follow-up of patients
who have Barrett’s esophagus. Chest Surg Clin North Am. 2002;12:
93-111.
68. O’Shaughnessy JA, Keloff GJ, Gordon GB, Dannenberg AJ, Hong
WK, Fabian CJ, et al. Treatment and prevention of intraepithelial
neoplasia: an important target for accelerated new agent development.
Clin Cancer Res. 2002;8:314-46
Discussion
Dr Stephen G. Swisher (Houston, Tex). I enjoyed your pre-
sentation. You know that p53 can be knocked out not only by
mutations and changes in protein, but by defects in downstream
genes that p53 turns on. Have you looked at any other of these
genes or are you planning to?
Dr Casson. Through the years we have looked at selected
genes. The p53 gene is the one that we have had the most
experience with in this sort of translational study. You are quite
right, the complexities of p53 are ever increasing, but we have not
looked at other pathways yet. We are more interested now in doing
that in the early stages, and I think that will be more profitable in
terms of, for example, chemopreventive strategies.
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Dr Steven J. Mentzer (Boston, Mass). You mentioned that
down the road you want to look at Barrett esophagus and look at
early-stage lesions, I presume. Do you see any heterogeneity in
terms of p53 expression within the tumors and perhaps adjacent
mucosa?
Dr Casson. Yes, and, in fact that was our original report in
Cancer Research. The mutations that we found in the tumor were
really quite discordant with the associated “premalignant tissues”
nearby. Again, it is heartening to see that others have reported the
same, and in head and neck cancer and lung cancer as well.
Heterogeneity is key to these sorts of studies. Certainly for Barrett
esophagus we are going to overcome this issue by laser capture
microdissection.
Dr Thomas K. Waddell (Toronto, Ontario, Canada). I com-
pliment you on being careful to separate your clinical material into
clinical categories, specifically type I and type II cardia or gastro-
esophageal junction tumors. Do you actually have any molecular
data on the type II tumors? Are they a distinct cancer from a p53 point
of view, or just from the perspective of clinical classification?
Dr Casson. The only work I am aware of was actually recently
published by Phillippe Taniere at the Cancer Agency, and he has
looked at p53, mdm-2, and a couple of other markers as yet
unpublished. He wrote this up in the American Journal of Pathol-
ogy, I think last year, and showed quite different profiles of
mutation in tumors that were categorized in that manner. I under-
stand that group has a collaborative project with Siewert’s group,
which again has a good series of well-stratified tumors. We have
not yet done that. In part, the number of cardia cancers I have
operated on during the last decade is much smaller. I have only 18
in my personal series, as opposed to the 91 esophageal tumors.
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